Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06679881 | Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | PHASE3 | RECRUITING | 170 | — | — | Feb 1, 2025 | Dec 1, 2028 | May 7, 2026 | 62 | United States, Argentina +20 |
| NCT06669754 | Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | PHASE3 | ACTIVE NOT_RECRUITING | 81 | — | — | Dec 1, 2024 | Aug 1, 2026 | Feb 13, 2026 | 56 | United States, Argentina +22 |
Hematology, blood chemistry, and urinalysis. Descriptive in nature, no formal statistical hypothesis testing will be performed.
Digital triplicate 12-lead ECG. Descriptive in nature, no formal statistical hypothesis testing will be performed.
| Arm | Type | Description |
|---|---|---|
| Deucrictibant | EXPERIMENTAL | Deucrictibant |
| Active | EXPERIMENTAL | Deucrictibant 40mg extended-release tablet by mouth once daily |
| Placebo | EXPERIMENTAL | Placebo 1 tablet by mouth once daily |
| Name | Type | Description |
|---|---|---|
| Deucrictibant | DRUG | Deucrictibant extended-release tablet for once daily oral use |
| Placebo | DRUG | Placebo |
Inclusion Criteria: 1. Provision of the signed ICF by the participant and/or legally designated representative. 2. Male or female, aged ≥12 years at the time of providing written informed consent/assent. 3. Diagnosis of hereditary angioedema (HAE) 4. For participants that did not participate in a p...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Intellia Therapeutics, Inc. | NTLA | 3 | PHASE3 | NTLA-2002, Normal Saline Administration, Biological NTLA-2002 |
| BioCryst Pharmaceuticals, Inc. | BCRX | 2 | PHASE3 | Berotralstat, berotralstat |
| Ionis Pharmaceuticals, Inc. | IONS | 1 | PHASE3 | Donidalorsen |
| KalVista Pharmaceuticals, Inc. | KALV | 1 | PHASE3 | KVD900, Drug: KVD900 |
| Pharvaris N.V. | PHVS | 1 | PHASE2 | deucrictibant |
| BioMarin Pharmaceutical Inc. | BMRN | 1 | PHASE1 | Dose 1 of BMN 331 |
| Astria Therapeutics, Inc. | ATXS | 1 | PHASE2 | STAR-0215 |